SAN DIEGO, July 13, 2018 /PRNewswire/ -- Biocept, Inc.
(NASDAQ: BIOC), a leading commercial provider of liquid biopsy
tests designed to provide physicians with clinically actionable
information to improve the outcomes of patients diagnosed with
cancer, announces a provider agreement with Alliance Global FZ, LLC
to market and distribute Biocept's Target Selector™ liquid biopsy
tests in the United Arab Emirates
and select countries in the Middle
East, North & Sub-Saharan Africa, and Southeast Asia (MEAA) region. All diagnostic
testing services under this agreement will be performed in
Biocept's San Diego-based
CLIA-certified laboratory with Alliance Global having
responsibility for sales, marketing, distribution, and
reimbursement of the Company's liquid biopsy platform. Additional
terms of the agreement were not disclosed.
"We are pleased to partner with Alliance Global to offer
patients diagnosed with cancer access to our patented liquid biopsy
testing," said Michael Nall,
President and CEO of Biocept. "We now have eight international
agreements enabling the distribution of our Target Selector™ tests
in 17 countries in addition to the U.S. We are enthusiastic about
the opportunities with a capable partner in this important region,
and given our strong global intellectual property position, we will
continue to be opportunistic in seeking to develop the market for
our liquid biopsy solutions internationally."
"Offering Biocept's novel liquid biopsy tests supports our
commitment to bringing innovative biomedical products and services
to emerging markets, and this agreement reflects Alliance Global's
focus on the growing clinical genomics sector in the MEAA region,"
said Dr. Nassim-Marie Hambouz, Group Director of commercial
operations at Alliance Global. "A major focus will be to use
Biocept's testing services to support global biopharmaceutical
companies in qualifying patients for their targeted therapies. We
feel that Biocept's Target Selector™ assays with industry-leading
sensitivity are uniquely suited for this application," added Dr.
Hambouz.
About Alliance Global
Alliance Global FZ, LLC distributes biomedical products &
services in the emerging markets of the Middle East, Africa and Asia (MEAA). The group is dedicated to
bringing innovative technologies to researchers, clinicians, and
diagnostic users across more than 60 countries in the MEAA region.
The group's stated mission is to improve the lives across emerging
markets through novel biomedical technologies.
About Biocept
Biocept, Inc. is a molecular diagnostics company with
commercialized assays for lung, breast, gastric, colorectal and
prostate cancers, and melanoma. The Company uses its
proprietary liquid biopsy technology to provide physicians with
information for treating and monitoring patients diagnosed with
cancer. The Company's patented Target Selector™ liquid biopsy
technology platform captures and analyzes tumor-associated
molecular markers in both circulating tumor cells (CTCs) and in
plasma (ctDNA). With thousands of tests performed, the
platform has demonstrated the ability to identify cancer mutations
and alterations to inform physicians about a patient's disease and
therapeutic options. For additional information, please visit
www.biocept.com.
Forward-Looking Statements Disclaimer Statement
This release contains forward-looking statements that are based
upon current expectations or beliefs, as well as a number of
assumptions about future events. Although we believe that the
expectations reflected in the forward-looking statements and the
assumptions upon which they are based are reasonable, we can give
no assurance that such expectations and assumptions will prove to
have been correct. Forward-looking statements are generally
identifiable by the use of words like "may," "will," "should,"
"could," "expect," "anticipate," "estimate," "believe," "intend,"
or "project" or the negative of these words or other variations on
these words or comparable terminology. To the extent that
statements in this release are not strictly historical, including
without limitation statements as to our ability to improve the
outcomes of patients diagnosed with cancer, the utility of our
intellectual property position, and our ability to develop the
market for our liquid biopsy solutions internationally, such
statements are forward-looking, and are made pursuant to the safe
harbor provisions of the Private Securities Litigation Reform Act
of 1995. The reader is cautioned not to put undue reliance on these
forward-looking statements, as these statements are subject to
numerous risk factors as set forth in our Securities and Exchange
Commission (SEC) filings. The effects of such risks and
uncertainties could cause actual results to differ materially from
the forward-looking statements contained in this release. We do not
plan to update any such forward-looking statements and expressly
disclaim any duty to update the information contained in this press
release except as required by law. Readers are advised to review
our filings with the SEC, which can be accessed over the Internet
at the SEC's website located at www.sec.gov.
View original content with
multimedia:http://www.prnewswire.com/news-releases/biocept-enters-into-agreement-with-alliance-global-fz-to-market-and-distribute-liquid-biopsy-testing-in-the-middle-east-southeast-asia-and-africa-region-300680550.html
SOURCE Biocept, Inc.